[18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma
12 augusti 2026 uppdaterad av: University of Washington
Imaging PARP Expression in Cholangiocarcinoma
This phase II trial studies whether [18F]FTT can be used with positron emission tomography (PET)/computed tomography (CT) imaging to predict treatment response in patients scheduled to receive gemcitabine, cisplatin, and durvalumab (GCD) for newly diagnosed cholangiocarcinoma.
PET/CT is an imaging technique that utilizes PET and CT in a single machine.
PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this trial, [18F]FTT, to make detailed, computerized pictures of areas inside the body where the tracer is used.
CT utilizes x-rays that traverse body from the outside.
CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in the patient's body.
[18F]FTT targets and binds to poly (ADP-ribose) polymerase 1 (PARP1).
Some cholangiocarcinoma tumor cells may express PARP1 which may make it easier to see them on PET/CT.
Research has shown that tumor cells that express PARP1 may not respond well to GCD treatment.
Researchers hope that by using [18F]FTT with PET/CT imaging they will be able to detect which patients have tumor cells that express PARP1, which may help predict treatment response in patients scheduled to receive GCD for newly diagnosed cholangiocarcinoma.
Studieöversikt
Status
Har inte rekryterat ännu
Betingelser
Detaljerad beskrivning
OUTLINE:
Patients receive [18F]FTT intravenously (IV) and 60, 90, or 150 minutes later undergo PET/CT within 30 days prior to day 1 cycle 1 of GCD and 12 weeks after starting GCD in the absence of unacceptable toxicity. Patients also undergo CT and/or magnetic resonance imaging (MRI) throughout the study.
After completion of study intervention, patients are followed up at week 24 and then up to 6 months after completing GCD treatment.
Studietyp
Interventionell
Inskrivning (Beräknad)
22
Fas
- Fas 2
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Angela Castellanos Rodriguez, MD, MSc
- Telefonnummer: 206-606-6777
- E-post: acastell@uw.edu
Studieorter
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98109
- Fred Hutch/University of Washington Cancer Consortium
-
Kontakt:
- Angela Castellanos Rodriguez, MD, MSc
- Telefonnummer: 206-606-6777
- E-post: acastell@uw.edu
-
Huvudutredare:
- Angela Castellanos Rodriguez, MD, MSc
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- Patient must have histologically confirmed cholangiocarcinoma
- Patient must be newly diagnosed and have not yet been treated
- Patient planned to receive GCD per standard-of-care
- Patient must have evaluable disease or at least one measurable lesion that can be assessed at baseline by CT (or MRI) per RECIST 1.1
- Age ≥ 18 years
- For women of childbearing potential, a negative serum pregnancy test is required within 7 days prior to [18F]FTT PET imaging
- Men and women of reproductive potential need to agree to employ acceptable forms of contraception throughout their participation in the study that meet requirements for GCD treatment per standard of care
- Patient is willing and able to comply with the protocol for the duration of the study including undergoing all study procedures
- Ability to understand and the willingness to sign a written informed consent document. Informed consent must be provided prior to any study specific procedures
Exclusion Criteria:
- Pregnant or breastfeeding women
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Diagnostisk
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Diagnostic ([18F]FTT PET/CT)
Patients receive [18F]FTT IV and 60, 90, or 150 minutes later undergo PET/CT within 30 days prior to day 1 cycle 1 of GCD and 12 weeks after starting GCD in the absence of unacceptable toxicity.
Patients also undergo CT and/or MRI throughout the study.
|
Genomgå MRI
Andra namn:
Genomgå PET/CT
Andra namn:
Givet IV
Andra namn:
Genomgå PET/CT och/eller CT
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Relationship between standardized uptake value maximum (SUVmax) and overall response rate
Tidsram: At baseline and 24 weeks after starting gemcitabine, cisplatin, and durvalumab (GCD)
|
Baseline SUVmax will be extracted from a region of interest (ROI) placed on the tumor lesion of interest using a 40% threshold.
Will assess overall response rate at 24 ± 2 weeks after starting GCD by using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.
Response will be analyzed as a binary outcome.
Differences in baseline SUVmax between responders and non-responders will be evaluated using the Wilcoxon rank-sum test.
Logistic regression models will be used to estimate the direction and magnitude of association, with response as the dependent variable and SUVmax as the predictor.
Odds ratios and 95% confidence intervals will be reported.
Analysis will focus on estimation of effect sizes and the direction and magnitude of associations of the primary endpoints, overall response rate and SUVmax of the most avid lesion, rather than formal hypothesis testing alone.
Boxplots will be used to visualize the distribution of SUVmax by responders group.
|
At baseline and 24 weeks after starting gemcitabine, cisplatin, and durvalumab (GCD)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Relationship between standardized uptake value mean (SUVmean) and overall response rate
Tidsram: At baseline and 24 weeks after starting GCD
|
Will measure baseline SUVmean from an ROI placed on the tumor lesion of interest using a 40% threshold.
Treatment response will be defined by RECIST 1.1 criteria at 24 ± 2 weeks following GCD treatment.
Association between baseline SUVmean and treatment response will be evaluated using Wilcoxon rank-sum test.
Logistic regression will be used to quantify the magnitude and direction of association between baseline SUVmean and response.
Results will be summarized using odds ratios with 95% confidence intervals, and boxplot to illustrate the distribution of baseline SUVmean between responders and non-responders.
|
At baseline and 24 weeks after starting GCD
|
|
Change in SUVmax and response
Tidsram: Baseline to 12 weeks after starting GCD
|
Will calculate the change of SUVmax from baseline to 12 ± 2 weeks after starting GCD.
Due to the limited sample size, will use the nonparametric method Wilcoxon Rank Sum test to evaluate the difference in change between responders and non-responders.
Effect sizes will be summarized using the median difference (Hodges-Lehmann estimator) in change between groups with 95% confidence intervals.
|
Baseline to 12 weeks after starting GCD
|
|
Change in SUVmean and response
Tidsram: Baseline to 12 weeks after starting GCD
|
Will calculate the change of SUVmean from baseline to 12 ± 2 weeks after starting GCD.
Due to the limited sample size, will use the nonparametric method Wilcoxon Rank Sum test to evaluate the difference in change between responders and non-responders.
Effect sizes will be summarized using the median difference (Hodges-Lehmann estimator) in change between groups with 95% confidence intervals.
|
Baseline to 12 weeks after starting GCD
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Huvudutredare: Angela Castellanos Rodriguez, MD, MSc, Fred Hutch/University of Washington Cancer Consortium
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Beräknad)
1 november 2026
Primärt slutförande (Beräknad)
1 juli 2028
Avslutad studie (Beräknad)
31 december 2028
Studieregistreringsdatum
Först inskickad
22 juni 2026
Först inskickad som uppfyllde QC-kriterierna
22 juni 2026
Första postat (Faktisk)
29 juni 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
14 augusti 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
12 augusti 2026
Senast verifierad
1 juni 2026
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- RG1126474
- NCI-2026-03509 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
- FHIRB0021301 (Annan identifierare: Fred Hutch/University of Washington Cancer Consortium)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Ja
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .